Section Arrow
PTN.NYSE-M
- Palatin Technologies
(Financial Status)
Quotes are at least 15-min delayed:2024/05/20 12:33 EDT
Last
 2.0216
+0.0216 (+1.08%)
Day High 
2.05 
Prev. Close
1-M High
2.48 
Volume 
25.43K 
Bid
2.02
Ask
2.03
Day Low
Open
1-M Low
1.66 
Market Cap 
32.27M 
Currency USD 
P/E -- 
%Yield
10-SMA 2.17 
20-SMA 2.01 
50-SMA 1.85 
52-W High 5.65 
52-W Low 1.43 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-2.72/-1.64
Enterprise Value
32.86M
Balance Sheet
Book Value Per Share
0.10
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
4.85M
Operating Revenue Per Share
0.30
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SCPXScorpius Holdings0.1416+0.0381+36.81%-- 
NBYNovaBay Pharmaceuticals0.1997+0.0811+68.38%-- 
GTBPGT Biopharma8.51+5.39+172.76%-- 
JAGXJaguar Health0.163-0.0955-36.94%0.48PE
KTRAKintara Therapeutics0.1647+0.0217+15.17%-- 
Quotes are at least 15-min delayed:2024/05/20 12:33 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type offemale sexual dysfunction.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.